Simple Search Results

Query String: HDAC4-KO

CHEMBL1159714 Ko 707 BDBM50421719
3-((3S,6S)-6-Isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indol-3-yl)-propionic acid tert-butyl ester BDBM50305083 3-((3S,6S,12aS)-6-Isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indol-3-yl)-propionic acid tert-butyl ester Ko143 Ko-143 US9695174, Ko143 CHEMBL488910

Macabuag, N; Esmieu, W; Breccia, P; Jarvis, R; Blackaby, W; Lazari, O; Urbonas, L; Eznarriaga, M; Williams, R; Strijbosch, A; Van de Bospoort, R; Matthews, K; Clissold, C; Ladduwahetty, T; Vater, H; Heaphy, P; Stafford, DG; Wang, HJ; Mangette, JE; McAllister, G; Beaumont, V; Vogt, TF; Wilkinson, HA; Doherty, EM; Dominguez, C Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington's Disease Pathology. J Med Chem 65: 12445-12459 (2022)
Abdel-Magid, AF Histone Deacetylase 4 (HDAC4) Inhibitors: A Promising Treatment for Huntington's Disease. ACS Med Chem Lett 4: 692-3 (2013)
Dolan, BM; Duron, SG; Campbell, DA; Vollrath, B; Shankaranarayana Rao, BS; Ko, HY; Lin, GG; Govindarajan, A; Choi, SY; Tonegawa, S Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. Proc Natl Acad Sci U S A 110: 5671-6
Marek, L; Hamacher, A; Hansen, FK; Kuna, K; Gohlke, H; Kassack, MU; Kurz, T Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem 56: 427-36 (2013)
Ontoria, JM; Altamura, S; Di Marco, A; Ferrigno, F; Laufer, R; Muraglia, E; Palumbi, MC; Rowley, M; Scarpelli, R; Schultz-Fademrecht, C; Serafini, S; Steinkühler, C; Jones, P Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy. J Med Chem 52: 6782-9 (2009)